SCHEMBL5833291

SCHEMBL5833291

CCOc1ccc(-c2ccc(OCC)cc2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.82
TSHR P16473 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
LTA4H P09960 2/20 0.58
XDH P47989 1/20 0.57
KDM4E B2RXH2 6/20 0.53
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
RAB9A P51151 4/20 0.53
TP53 P04637 3/20 0.53
NPC1 O15118 3/20 0.53
HPGD P15428 3/20 0.53
PARP10 Q53GL7 1/20 0.52
RELA Q04206 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
PRSS1 P07477 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9155582 1.00 NQO1 (0.82) NQO1TSHRTDP1LTA4HXDH
SCHEMBL18417193 1.00 NQO1 (0.82) NQO1TSHRTDP1LTA4HXDH
SCHEMBL13048467 0.92 NQO1 (0.70) NQO1TSHRTDP1LTA4HXDH
1,4-Diethoxybenzene SCHEMBL124015 0.91 NQO1 (1.00) NQO1TSHRTDP1LTA4HKDM4E
1,4-Diethoxybenzene SCHEMBL28186701 0.91 NQO1 (1.00) NQO1TSHRTDP1LTA4HKDM4E
SCHEMBL9152440 0.90 LTA4H (0.68) NQO1TSHRTDP1LTA4HKDM4E
SCHEMBL12726668 0.90 LTA4H (0.68) NQO1TSHRTDP1LTA4HKDM4E
SCHEMBL404478 0.90 NQO1 (0.67) NQO1TSHRTDP1LTA4HXDH
SCHEMBL2492122 0.90 NQO1 (0.67) NQO1TSHRTDP1LTA4HXDH
SCHEMBL12736285 0.90 NQO1 (0.67) NQO1TSHRTDP1LTA4HXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117534547-B Hetero [3] arene macrocyclic compound, and preparation method and application thereof 东北大学 2025-04-08 CN claimed
CN-117766187-A Adsorption method of methyl iodide 东北大学 2024-03-26 CN claimed
CN-117534547-A Hetero [3] arene macrocyclic compound, and preparation method and application thereof 东北大学 2024-02-09 CN claimed
CN-115286493-A Preparation method of 4,4' -diethoxybiphenyl 北京格林凯默科技有限公司 2022-11-04 CN claimed
CN-119977743-A Method for rapidly preparing biphenyl compounds by catalyzing C-C coupling reaction through mechanical grinding method 辽宁大学 2025-05-13 CN disclosed
CN-117534547-B Hetero [3] arene macrocyclic compound, and preparation method and application thereof 东北大学 2025-04-08 CN disclosed
CN-117766187-A Adsorption method of methyl iodide 东北大学 2024-03-26 CN disclosed
CN-117534547-A Hetero [3] arene macrocyclic compound, and preparation method and application thereof 东北大学 2024-02-09 CN disclosed
CN-115286493-A Preparation method of 4,4' -diethoxybiphenyl 北京格林凯默科技有限公司 2022-11-04 CN disclosed
CN-115286493-A Preparation method of 4,4' -diethoxybiphenyl 北京格林凯默科技有限公司 2022-11-04 CN disclosed
CN-115286493-A Preparation method of 4,4' -diethoxybiphenyl 北京格林凯默科技有限公司 2022-11-04 CN disclosed
US-10578774-B2 Retardation-increasing agent, cellulose-based resin composition using same, and film ADEKA CORPORATION (JP) 2020-03-03 US disclosed
US-6964967-B2 Substituted pyrido[2,3-d]pyrimidines and methods for their use AMGEN, INC. (US) 2005-11-15 US disclosed
US-20050075333-A1 CXCR3 antagonists TULARIK INC. 2005-04-07 US disclosed
US-6794379-B2 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; SKIN DISORDERS TULARIK INC. 2004-09-21 US disclosed
EP-1343505-A1 CXCR3 ANTAGONISTS Tularik Inc. (US) 2003-09-17 EP disclosed
US-20030069234-A1 CXCR3 antagonists AMGEN INC. 2003-04-10 US disclosed
US-20030055054-A1 CXCR3 antagonists TULARIK, INC. 2003-03-20 US disclosed
US-20020169159-A1 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor TULARIK INC. (US) 2002-11-14 US disclosed
WO-2002083143-A1 CXCR3 ANTAGONISTS TULARIK INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075333-A1 CXCR3 antagonists CXCR3, CXCR1, CCR5 NQO1 3414/4885TSHR 975/4885TDP1 3854/4885
US-20030069234-A1 CXCR3 antagonists CXCR3, CXCR1, CCR5 NQO1 3414/4885TSHR 975/4885TDP1 3854/4885
US-20020169159-A1 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor CCR2, CCR1, ACKR3 NQO1 2997/4885TSHR 1129/4885TDP1 4230/4885
US-20030055054-A1 CXCR3 antagonists CXCR3, CXCR1, CCR5 NQO1 3414/4885TSHR 975/4885TDP1 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.